
EquitySector - HealthcareVery High Risk
Direct
NAV (09-Oct-26)
Returns (Since Inception)
Fund Size
₹332 Cr
Expense Ratio
1.22%
ISIN
INF194KB1KF5
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Nov 2025
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+8.36%
— (Cat Avg.)
| Equity | ₹318.21 Cr | 95.97% |
| Others | ₹13.37 Cr | 4.03% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹34.73 Cr | 10.48% |
| Cipla Ltd | Equity | ₹21.14 Cr | 6.38% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹19.28 Cr | 5.81% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹18.69 Cr | 5.64% |
| Triparty Repo Trp_010926 | Cash - Repurchase Agreement | ₹14.36 Cr | 4.33% |
| Divi's Laboratories Ltd | Equity | ₹14.2 Cr | 4.28% |
| Aurobindo Pharma Ltd | Equity | ₹13.74 Cr | 4.14% |
| Lupin Ltd | Equity | ₹13.13 Cr | 3.96% |
| Shilpa Medicare Ltd | Equity | ₹12.34 Cr | 3.72% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹12.2 Cr | 3.68% |
| Dr Reddy's Laboratories Ltd | Equity | ₹11.54 Cr | 3.48% |
| Torrent Pharmaceuticals Ltd | Equity | ₹11.15 Cr | 3.36% |
| Gland Pharma Ltd | Equity | ₹10.1 Cr | 3.05% |
| Zydus Lifesciences Ltd | Equity | ₹9.21 Cr | 2.78% |
| Narayana Hrudayalaya Ltd | Equity | ₹8.58 Cr | 2.59% |
| Global Health Ltd | Equity | ₹8.14 Cr | 2.45% |
| Syngene International Ltd | Equity | ₹8.02 Cr | 2.42% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹7.78 Cr | 2.35% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹7.44 Cr | 2.24% |
| Rainbow Childrens Medicare Ltd | Equity | ₹7.07 Cr | 2.13% |
| Pfizer Ltd | Equity | ₹6.09 Cr | 1.84% |
| Ajanta Pharma Ltd | Equity | ₹5.76 Cr | 1.74% |
| HealthCare Global Enterprises Ltd | Equity | ₹5.5 Cr | 1.66% |
| Sanofi India Ltd | Equity | ₹5 Cr | 1.51% |
| Novartis India Ltd | Equity | ₹4.96 Cr | 1.50% |
| Ipca Laboratories Ltd | Equity | ₹4.94 Cr | 1.49% |
| Jubilant Pharmova Ltd | Equity | ₹4.85 Cr | 1.46% |
| Thyrocare Technologies Ltd | Equity | ₹4.84 Cr | 1.46% |
| Alivus Life Sciences Ltd | Equity | ₹4.52 Cr | 1.36% |
| AstraZeneca Pharma India Ltd | Equity | ₹4.17 Cr | 1.26% |
| Sai Life Sciences Ltd | Equity | ₹3.65 Cr | 1.10% |
| Orchid Pharma Ltd | Equity | ₹3.59 Cr | 1.08% |
| Sai Parenteral's Ltd | Equity | ₹3.16 Cr | 0.95% |
| Medi Assist Healthcare Services Ltd | Equity | ₹2.96 Cr | 0.89% |
| Dr. Lal PathLabs Ltd | Equity | ₹2.9 Cr | 0.88% |
| Viyash Scientific Ltd | Equity | ₹2.83 Cr | 0.85% |
| Net Current Assets | Cash | ₹-1.08 Cr | 0.33% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0.09 Cr | 0.03% |
Large Cap Stocks
30.13%
Mid Cap Stocks
31.92%
Small Cap Stocks
33.92%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹318.21 Cr | 95.97% |
Standard Deviation
This fund
--
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better

Since November 2025
Since November 2025
Since November 2025
Since November 2025
ISIN INF194KB1KF5 | Expense Ratio 1.22% | Exit Load No Charges | Fund Size ₹332 Cr | Age 10 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,24,618 Cr
Address
6th Floor, 841, One World Center, Mumbai, 400013
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments